XPA and cancer: Considering the importance of XPA for both NER sub-pathways, inhibition of the scaffolding activity of XPA by small molecules, their combination with DNA damaging anticancer agents, controlling the subcellular level of XPA, its cytosolic-to-nuclear translocation and stabilization, and finely tuned regulation of XPA PTMs and their crosstalk, may all represent novel promising approaches for the improvement of cancer treatment outcome.